Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lomitapide
Drug ID BADD_D01311
Description Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Indications and Usage Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
Marketing Status approved; investigational
ATC Code C10AX12
DrugBank ID DB08827
KEGG ID D09637
MeSH ID C473731
PubChem ID 9853053
TTD Drug ID D0H8VY
NDC Product Code Not Available
UNII 82KUB0583F
Synonyms BMS201038 | BMS-201038 | BMS 201038 | lomitapide | Juxtapid | AEGR 733 | AEGR733 | AEGR-733
Chemical Information
Molecular Formula C39H37F6N3O2
CAS Registry Number 182431-12-5
SMILES C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C (=O)NCC(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chromaturia20.02.01.0020.000084%
Chronic obstructive pulmonary disease22.03.01.0070.000021%-
Constipation07.02.02.0010.000786%
Coronary artery occlusion02.02.01.006; 12.02.01.036; 24.04.04.0130.000021%-
Cough22.02.03.0010.000443%
Defaecation urgency07.02.04.0010.000047%-
Dehydration14.05.05.0010.000203%
Depressed mood19.15.02.0010.000069%-
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.0010.009782%
Discomfort08.01.08.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.000760%
Drug interaction08.06.03.001---
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dyspepsia07.01.02.0010.000568%
Dysphagia07.01.06.0030.000178%
Ear disorder04.03.01.001---
Eating disorder14.03.01.008; 19.09.01.0080.000047%-
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002---
Eructation07.01.02.0030.000084%
Eye disorder06.08.03.001---
Eye swelling06.08.03.003---
Faeces discoloured07.01.03.0020.000109%-
Faeces hard07.01.03.003---
Fatigue08.01.01.0020.001105%
Feeling abnormal08.01.09.014---
Flatulence07.01.04.0020.002020%
Fluid retention14.05.06.002; 20.01.02.0030.000021%-
Frequent bowel movements07.02.04.0020.000131%-
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene